Literature DB >> 30819455

Lung Cancer Screening in the National Cancer Institute Community Oncology Research Program: Availability and Service Organization.

Ruth C Carlos1, JoRean D Sicks2, Caroline Chiles3, Lucy Gansauer4, Charles S Kamen5, Anne E Kazak6, Heather B Neuman7, Joseph M Unger8, Kathryn E Weaver9.   

Abstract

PURPOSE: Annual low-dose CT (LDCT) for lung screening in high-risk individuals decreases both lung cancer-specific mortality and all-cause mortality. Community oncology practice networks constituting the National Cancer Institute Community Oncology Research Program (NCORP) conduct clinical trials across the cancer spectrum. The authors report access to and characteristics of LDCT screening for lung cancer in these community oncology practices.
METHODS: A landscape capacity assessment was conducted in 2017 across the NCORP network. The primary outcome was the proportion of adult oncology practice groups offering LDCT lung screening on site. The secondary outcomes were the proportion of those screening services (1) with radiologist participation in service management and (2) offered at ACR Designated Lung Cancer Screening Centers.
RESULTS: Fifty-two percent of components and subcomponents responded to at least some portion of the assessment, representing 217 practice groups. Analyzing the 211 adult oncology practice groups responding to the primary question, 73% offered lung screening services on site. Radiologists participated in managing 69% of these services. Forty-seven percent were offered in ACR Designated Lung Cancer Screening Centers. Minority and underserved practice groups were less likely to offer lung screening; however, this association dissipated when analyses focused on practices within the United States. Safety net and Critical Access Hospital designation increased the likelihood of screening availability.
CONCLUSIONS: The majority of community oncology practice groups within the NCORP offered lung screening on site, although radiologist participation in service management and ACR Lung Cancer Screening Center designation, markers of service quality, were more variable.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  LDCT; Lung cancer screening; NCORP; disparities; safety net

Mesh:

Year:  2019        PMID: 30819455      PMCID: PMC6688499          DOI: 10.1016/j.jacr.2018.12.016

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  19 in total

1.  Are there differences in the Medicare experiences of beneficiaries in Puerto Rico compared with those in the U.S. mainland?

Authors:  Marc N Elliott; Amelia M Haviland; Jacob W Dembosky; Katrin Hambarsoomian; Robert Weech-Maldonado
Journal:  Med Care       Date:  2012-03       Impact factor: 2.983

2.  The National Lung Screening Trial: overview and study design.

Authors:  Denise R Aberle; Christine D Berg; William C Black; Timothy R Church; Richard M Fagerstrom; Barbara Galen; Ilana F Gareen; Constantine Gatsonis; Jonathan Goldin; John K Gohagan; Bruce Hillman; Carl Jaffe; Barnett S Kramer; David Lynch; Pamela M Marcus; Mitchell Schnall; Daniel C Sullivan; Dorothy Sullivan; Carl J Zylak
Journal:  Radiology       Date:  2010-11-02       Impact factor: 11.105

3.  The impact of primary care resources on prevention practices.

Authors:  Lynn M Soban; Elizabeth M Yano
Journal:  J Ambul Care Manage       Date:  2005 Jul-Sep

4.  Lung cancer screening using low-dose CT: the current national landscape.

Authors:  Jan M Eberth; Rebecca Qiu; Swann A Adams; Ramzi G Salloum; Nathanial Bell; Amanda K Arrington; Suzanne K Linder; Reginald F Munden
Journal:  Lung Cancer       Date:  2014-07-21       Impact factor: 5.705

Review 5.  Organizational factors and the cancer screening process.

Authors:  Rebecca Anhang Price; Jane Zapka; Heather Edwards; Stephen H Taplin
Journal:  J Natl Cancer Inst Monogr       Date:  2010

6.  Do integrated medical groups provide higher-quality medical care than individual practice associations?

Authors:  Ateev Mehrotra; Arnold M Epstein; Meredith B Rosenthal
Journal:  Ann Intern Med       Date:  2006-12-05       Impact factor: 25.391

7.  Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening.

Authors:  Fabrice Smieliauskas; Heber MacMahon; Ravi Salgia; Ya-Chen Tina Shih
Journal:  J Med Screen       Date:  2014-08-12       Impact factor: 2.136

8.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

9.  Primary care practice organization influences colorectal cancer screening performance.

Authors:  Elizabeth M Yano; Lynn M Soban; Patricia H Parkerton; David A Etzioni
Journal:  Health Serv Res       Date:  2007-06       Impact factor: 3.402

10.  Barriers to colorectal cancer screening in rural primary care.

Authors:  K Allen Greiner; Kimberly K Engelman; Matthew A Hall; Edward F Ellerbeck
Journal:  Prev Med       Date:  2004-03       Impact factor: 4.018

View more
  2 in total

1.  Organizational Characteristics and Smoking Cessation Support in Community-Based Lung Cancer Screening Programs.

Authors:  Christina Bellinger; Kristie Long Foley; Emily V Dressler; Carol Kittel; David P Miller; Kathryn E Weaver; Erin L Sutfin; W Jeffrey Petty; John Spangler; Rebecca Stone; Daniel M Anderson; Heather Kehn; Cindy Steenstra; Rajiv Panikkar; Caroline Chiles
Journal:  J Am Coll Radiol       Date:  2022-03-02       Impact factor: 5.532

2.  The Head and Neck Survivorship Tool (HN-STAR) Trial (WF-1805CD): A protocol for a cluster-randomized, hybrid effectiveness-implementation, pragmatic trial to improve the follow-up care of head and neck cancer survivors.

Authors:  Talya Salz; Jamie S Ostroff; Chandylen L Nightingale; Thomas M Atkinson; Eleanor C Davidson; Sankeerth R Jinna; Anuja Kriplani; Glenn J Lesser; Kathleen A Lynch; Deborah K Mayer; Kevin C Oeffinger; Sujata Patil; Andrew L Salner; Kathryn E Weaver
Journal:  Contemp Clin Trials       Date:  2021-05-21       Impact factor: 2.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.